Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Open evidence library

Search the archive.

Current and older evidence is free during beta. Sign in for unlimited card access and full source downloads.

Matching cards
2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Disease Defense

No disease extinction --- empirics and isolated populations

Nick Beckstead 14, Research Fellow at the Future of Humanity Institute, citing Peter Doherty, recipient of the 1996 Nobel Prize for Medicine, PhD in Immunology from the University of Edinburgh, Michael F. Tamer Chair of Biomedical Research at St. Jude Children’s Research Hospital, “How much could refuges help us recover from a global catastrophe?” in Futures, published online 18 Nov 2014, Science Direct

That leaves pandemics and cobalt bombs, which will get a longer discussion. While there is little published work on human extinction risk from pandemics, it seems that it would be extremely challenging for any pandemic—whether natural or manmade—to leave the people in a specially constructed refuge as the sole survivors. In his introductory book on pandemics (Doherty, 2013, p. 197) argues:¶ “No pandemic is likely to wipe out the human species. Even without the protection provided by modern science, we survived smallpox, TB, and the plagues of recorded history. Way back when human numbers were very small, infections may have been responsible for some of the genetic bottlenecks inferred from evolutionary analysis, but there is no formal proof of this.”¶ Though some authors have vividly described worst-case scenarios for engineered pandemics (e.g. Rees, 2003 and Posner, 2004; and Myhrvold, 2013), it would take a special effort to infect people in highly isolated locations, especially the 100+ “largely uncontacted” peoples who prefer to be left alone. This is not to say it would be impossible. A madman intent on annihilating all human life could use cropduster-style delivery systems, flying over isolated peoples and infecting them. Or perhaps a pandemic could be engineered to be delivered through animal or environmental vectors that would reach all of these people.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Disease Defense

Disease no extinction

Amesh Adalja 16, infectious-disease physician at the University of Pittsburgh, 6/17/16, “Why Hasn't Disease Wiped out the Human Race?,” https://www.theatlantic.com/health/archive/2016/06/infectious-diseases-extinction/487514/

But when people ask me if I’m worried about infectious diseases, they’re often not asking about the threat to human lives; they’re asking about the threat to human life. With each outbreak of a headline-grabbing emerging infectious disease comes a fear of extinction itself. The fear envisions a large proportion of humans succumbing to infection, leaving no survivors or so few that the species can’t be sustained.

I’m not afraid of this apocalyptic scenario, but I do understand the impulse. Worry about the end is a quintessentially human trait. Thankfully, so is our resilience.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Disease Defense

Their evidence assumes a level of virulence that has literally never occurred

Wendy Orent 15, anthropologist and freelance science writer whose work has appeared in The Washington Post, The LA Times, The New Republic, Discover, and The American Prospect, instructor in science journalism @ Emory, Ignore predictions of lethal pandemics and pay attention to what really matters, LA Times, 1/3/15, http://www.latimes.com/opinion/op-ed/la-oe-orent-pandemic-hysteria-20150104-story.html

Prophets of doom have been telling us for decades that a deadly new pandemic — of bird flu, of SARS or MERS coronavirus, and now of Ebola — is on its way. Why are we still listening? If you look back at the furor raised at many distinguished publications — Nature, Science, Scientific American, National Geographic — back in, say, 2005, about a potential bird flu (H5N1) pandemic, you wonder what planet they were on. Nature ran a special section titled — “Avian flu: Are we ready?” — that began, ominously, with the words “Trouble is brewing in the East” and went on to present a mock aftermath report detailing catastrophic civil breakdown. Robert Webster, a famous influenza virologist, told ABC News in 2006 that “society just can't accept the idea that 50% of the population could die. And I think we have to face that possibility.” Public health expert Michael T. Osterholm of the University of Minnesota, at a meeting in Washington of scientists brought together by the Institute of Medicine, warned in 2005 that a post-pandemic commission, like the post-9/11 commission, could hold “many scientists … accountable to that commission for what we did or didn't do to prevent a pandemic.” He also predicted that we could be facing “three years of a given hell” as the world struggled to right itself after the deadly pandemic. And Laurie Garrett, author of what must be the urtext for pandemic predictions, her 1994 book “The Coming Plague,” intoned in Foreign Affairs that “in short, doom may loom.” Although she followed that with “But note the may,” the article went on to paint a terrifying picture of the avian flu threat nonetheless. And such hysteria still goes on: Whether it's over the MERS coronavirus, a whole alphabet of chicken flu viruses, a real but not very deadly influenza pandemic in 2009, or a kerfuffle like the one in 2012 over a scientist-crafted ferret flu that also was supposed to be a pandemic threat. Along the way, virologist Nathan Wolfe published “The Viral Storm: the Dawn of a New Pandemic Age,” and David Quammen warned in his gripping “Spillover” that some new animal plague could arise from the jungle and sweep across the world. And now there's Ebola. Osterholm, in a widely read op-ed in the New York Times in September, wrote about the possibility that scientists were afraid to mention publicly the danger they discuss privately: that Ebola “could mutate to become transmissible through the air.” “The Ebola epidemic in West Africa has the potential to alter history as much as any plague has ever done,” he wrote. And Garrett wrote in Foreign Policy, “Attention, World: You just don't get it.” She went on to say, “Wake up, fools,” because we should be more frightened of a potential scenario like the one in the movie “Contagion,” in which a lethal, fictitious pandemic scours the world, nearly destroying civilization. But there were fewer takers this time. Osterholm's claims about Ebola going airborne were discounted by serious scientists, and Garrett seemingly retracted her earlier hysteria about Ebola by claiming that, after all, evolution made such spread unlikely. The scientific world has changed since 2005. Now, most scientists understand that there are significant physical and evolutionary barriers to a blood- and fluid-borne virus developing airborne transmission, as Garrett has acknowledged. Though Ebola virus has been detected in human alveolar cells, as Vincent Racaniello, virologist at Columbia University, explained to me, that doesn't mean it can replicate in the airways enough to allow transmission. “Maybe … the virus can get in, but can't get out. Like a roach motel,” wrote Racaniello in an email. H5N1, we understand now, never went airborne because it attached only to cell receptors located deep in human lungs, and could not, therefore, be coughed or sneezed out. SARS, or severe acute respiratory syndrome, caused local outbreaks after multiple introductions via air travel but spread only sluggishly and mostly in hospitals. Breaking its chains of transmission ended the outbreak globally. There probably will always be significant barriers preventing the easy adaptation of an animal disease to the human species. Furthermore, Racaniello insists that there are no recorded instances of viruses that have adapted to humans, changing the way they are spread. So we need to stop listening to the doomsayers, and we need to do it now. Predictions of lethal pandemics have — since the swine flu fiasco of 1976, when President Ford vowed to vaccinate “every man, woman and child in the United States” — always been wrong. Fear-mongering wastes our time and our emotions and diverts resources from where they should be directed — in the case of Ebola, to the ongoing tragedy in West Africa. Americans have all but forgotten about Ebola now, because most people realize it isn't coming to a school or a shopping mall near you. But Sierra Leoneans and Liberians go on dying.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 1NC---Disease Defense

Infectious diseases don’t cause extinction

Owen Cotton-Barratt 17, et al, PhD in Pure Mathematics, Oxford, Lecturer in Mathematics at Oxford, Research Associate at the Future of Humanity Institute, 2/3/2017, Existential Risk: Diplomacy and Governance, https://www.fhi.ox.ac.uk/wp-content/uploads/Existential-Risks-2017-01-23.pdf

For most of human history, natural pandemics have posed the greatest risk of mass global fatalities.37 However, there are some reasons to believe that natural pandemics are very unlikely to cause human extinction. Analysis of the International Union for Conservation of Nature (IUCN) red list database has shown that of the 833 recorded plant and animal species extinctions known to have occurred since 1500, less than 4% (31 species) were ascribed to infectious disease.38 None of the mammals and amphibians on this list were globally dispersed, and other factors aside from infectious disease also contributed to their extinction. It therefore seems that our own species, which is very numerous, globally dispersed, and capable of a rational response to problems, is very unlikely to be killed off by a natural pandemic.

One underlying explanation for this is that highly lethal pathogens can kill their hosts before they have a chance to spread, so there is a selective pressure for pathogens not to be highly lethal. Therefore, pathogens are likely to co-evolve with their hosts rather than kill all possible hosts.39

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Immigration AC

Peterson concludes it’s the Achilles heel of bioterror preparedness

Kimberly Ann Petersen 14, MA thesis in Security Studies, “THE AFFORDABLE CARE ACT: A PRESCRIPTION FOR HOMELAND SECURITY PREPAREDNESS?,” Naval Postgraduate School

One of the most notable gaps in the Affordable Care Act is its failure to cover the immigrant population. Over 11 million illegal immigrants are not eligible for any of the ACA benefits, and they are specifically prohibited from purchasing health insurance on the exchanges. Even legal immigrants must establish residency for five years before gaining eligibility for ACA benefits. According to Shane Green, communities without access to care “are more vulnerable to infectious diseases and therefore might be considered the nation’s Achilles’ heel in a bioterrorism attack.”221 The same is true for any infectious disease, regardless of source.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Immigration AC

Its normal means and turns solvency---Even the most radical proposals for single payer are founded on the exclusion of non-citizens which leaves 23 million uncovered

Amanda Michelle Gomez 17, Health reporter at ThinkProgress, 9/14/17, “Defining the ‘all’ in ‘Medicare for All’,” https://thinkprogress.org/while-attention-turns-to-health-care-for-all-lets-talk-about-coverage-for-immigrants-d1d5724cc743/

As progressives consider proposals to implement universal health care, it’s important to define the principle that’s driving them. What unites Democrats right now is the idea that health care is a right afforded to all. If that’s the self-imposed litmus test, it’s essential to define “all” when discussing universal health care.

Millions of people who live in the United States are currently uninsured. High costs remain a major barrier to coverage; 46 percent of uninsured adults said costs were a primary reason according to a 2015 Kaiser Family Foundation poll. Proposals by Sens. Bernie Sanders (D-VT) and Brian Schatz (D-HI), who are advocating to expand public programs like Medicare and Medicaid, respectively, strive to make care affordable.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 1NC---Immigration AC

The aff leaves millions of undocumented immigrants uninsured---its normal means

Jacob Perrin 13, MA in Bioethics from Wake Forest University, December 2013, “Are We Forgetting Someone? Undocumented Immigrants and Health Care,”

On September 9th in 2009, President Obama addressed a joint session of Congress in support of the pending health reform legislation.1 At one point in the speech, President Obama addressed the implications of healthcare reform for undocumented immigrants (UIs)— immigrants who either entered the U.S. without valid documents or who are living outside the terms of their visa—saying, “There are also those who claim that our reform effort will insure illegal immigrants. This, too, is false—the reforms I’m proposing would not apply to those here illegally.” In one of the more memorable moments of the health reform debate, Congressman Joe Wilson of South Carolina yelled out, “You lie!” upon hearing the President’s words. Was Wilson right? What kind of healthcare do UIs have? And most importantly, what kind of healthcare should UIs have? These are the kinds of questions I hope to address throughout this thesis.

Ironically enough, this public moment of dissension between Wilson and Obama was, in reality, one of the few tenets of the law upon which Republicans and Democrats could agree. Although the Patient Protection and Affordable Care Act (ACA) will make a considerable dent in our uninsured population, UIs[undocumented immigrants] are unlikely to be among the newly insured. The ACA continues to restrict Medicaid access for UIs[undocumented immigrants] and explicitly bars them from participating in the new health insurance exchanges, even if they are willing to pay with their own money. Because of this, UIs[undocumented immigrants] will comprise an increasingly disproportionate share of the uninsured. This post-reform climate seems to be an opportune time to consider whether or not our general indifference to the healthcare of UIs[undocumented immigrants] is justified, or whether we need to reevaluate our position.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Turns Bioterror/Disease

Turns bioterror and disease

Heritage 8---Heritage Foundation, Think Tank, 1/18/08, “Health Care and Homeland Security: Crossroads of Emergency Response,” http://www.heritage.org/homeland-security/report/health-care-and-homeland-security-crossroads-emergency-response

The medical practitioner (physicians, nurses, physician assistants, nurse practitioners, mental health care work­ers) is under siege. Costs of liability insurance, decreasing reimbursements, the "hassle factor" of increased red tape and regulation, and the increasing costs of practice are driving individuals out of the system. EDs currently have vacancies in 13 percent of their staff positions. And Community Health Centers have over 2,500 current clinical vacancies across the country.

Today, the health care sector is facing a severe shortage of nurses. Many nurses are approaching retirement age and the nursing profession faces difficulties both attracting new entrants and retaining the existing workforce. As a result, the nurse supply remains flat. This results in serious regional shortages. For example, the state of California has a 15 percent to 20 percent nursing vacancy rate at hospitals today, and there are estimates that it will reach 46 percent by 2020.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Turns Bioterror/Disease

Turns case---worsens quality and access to care

Amy Anderson 14, Health Policy Expert and Consultant, AACN Faculty Policy Think Tank Member, Assistant Professor of Professional Practice at Texas Christian University, 3/18/14, “The Impact of the Affordable Care Act on the Health Care Workforce” http://www.heritage.org/health-care-reform/report/the-impact-the-affordable-care-act-the-health-care-workforce

Unintended Consequences. Adding up to 34 million patients to an insurance and delivery system that is already struggling with workforce shortages cannot avoid adversely affecting patient access and quality of care. The ACA cannot by itself guarantee access or increased quality of care through the mandated purchase of all-inclusive insurance policies. In fact, the unintended consequences of the ACA’s complexity will ripple throughout the health care sector.

Quality Health Care. Quality of care has been a major focus in health care in the U.S. for many years, and America’s medical professionals have continually tried to improve practice and provide the best care in the world. Nonetheless, the results have been uneven.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Doctor Shortages Link

If they’re right that physicians and hospitals get paid much less under the aff, that causes shortages of medical services which crush the case

Robert A. Book 9, Senior Research Fellow in Health Economics. 4/3/9, “Single Payer: Why Government-Run Health Care Will Harm Both Patients and Doctors” http://www.heritage.org/health-care-reform/report/single-payer-why-government-run-health-care-will-harm-both-patients-and

Physician advocacy groups make the reasonable-and believable-argument that every reduction in the Medicare payment rates will result in a further reduction in the number of physicians who find it worthwhile to take Medicare patients and instead try to make their living from patients with private payers. A survey found that in response to a proposed 10 percent cut in Medicare rates, 28 percent of physicians would stop accepting new Medicare patients, 8 percent would stop treating Medicare patients already under their care, and much higher percentages would discontinue nursing home visits, reduce available hours, or defer investment in medical and health IT equipment.[11]

Obviously, this would not affect physicians in all specialties equally. Most pediatricians have very few if any Medicare patients[12] and would hardly be affected at all, but cardiologists and oncologists, for example, would be hit hard, since a large percentage of their potential patients are over age 65. The impact on nephrologists would be especially severe, because anyone with end-state renal disease is covered by Medicare regardless of age. Yet for every reduction in the payment level, a few more physicians would find it better to drop Medicare than to stay in.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 2NC---Doctor Shortages Link

The only way to control costs is to limit access to health care---that crushes the case

Dave Mordo 17, Director of Compliance & Broker Education, insurance company. 7/25/17, “Single-payer would be a nightmare for Americans” http://www.washingtonexaminer.com/single-payer-would-be-a-nightmare-for-americans/article/2629120

Single-payer systems control costs primarily by limiting access to healthcare. In the United Kingdom's National Health Service, 5 million patients will languish on waiting lists for non-emergency surgeries, such as hip replacements, by 2019. The president of the country's emergency room doctors association warned earlier this year that wait times are causing "untold patient misery" and that the NHS is "broken."

In Canada, patients wait more than nine weeks between referral from a general practitioner and consultation with a specialist. By comparison, American patients wait less than four weeks, on average. Fewer than 4 percent of Americans who need non-emergency surgeries must wait longer than four months, compared to 18 percent of Canadians.

2023 Northwestern Affirmative
Case › Disease Advantage---Defense › 1NC---Doctor Shortages

The plan causes doctors to quit and crushes R&D---turns access and outcomes

Christopher Castaldi-Moller 16, Bridge the Divide, 11/14/16, “Against Single Payer,” https://www.bridge-the-divide.com/single-post/2016/11/14/Against-Single-Payer

Secondly, the ways through which some progressives propose to cut potential medical expenses are either infeasible or immensely problematic. Relying on an incredibly high reduction in pharmaceutical costs in America wouldn’t be very wise – while prices would surely go down under single-payer, they can’t such that the budgetary impacts of a national healthcare scheme would be minimal. What the government could do instead is cut the paychecks of American doctors to ensure that the cost of single payer can be at least slightly contained. But this would, of course, be an utter disaster for a broad variety of reasons. First, by reducing medical salaries, America's hospitals and clinics would see doctors either exit the profession or retire early. This is not a speculative forecast – as Dr. Robert Book of the Heritage Foundation explains, low Medicare and Medicaid payouts induce doctors to drop those patients covered by the two public plans in favor of the privately insured. Under a single payer system, the fact that there would be no private alternatives means that doctors might have no choice but to leave their field if they are frustrated by lowered salaries. Meanwhile, the deterrent effect caused by reduced physician pay would mean that many talented individuals – confronted with a plethora of lucrative career opportunities and the arduous process of earning a medical degree – may simply opt out of becoming doctors in the first place. In the short term, this would harm patient access to their doctors of choice, cause a ‘brain drain’ of experienced and trained doctors, and reduce the time doctors spend on individual patients by decreasing the supply of medical professionals. But more dangerously, a reduced pool of medical professionals and a cut profit incentive would cause reduced focus on and investment in advanced medical equipment and research projects. This would not only mean that specialized and cosmetic care would be hindered under a single payer scheme, but that the rate of treatment and cure discovery would be slowed. Therefore, single payer may not only cost Americans their favorite doctors, but it will also cost lives by slowing medical research.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---US Key

US is the key driver of global medical innovation

Glen Whitman 10, associate professor of economics at California State University, Northridge, and Raymond Raad, M.D., M.P.H., resident in psychiatry at New York Presbyterian Hospital / Weill Cornell Medical Center, Jan 6 2010, “The Healing Power Of Innovation,” http://www.forbes.com/2010/01/06/health-care-reform-congress-politics-opinions-contributors-whitman-raad.html

As congressional Democrats prepare to revamp America’s health care sector, few have addressed how their plans might affect medical innovation. The United States leads the world in such innovation, generating most of the medical discoveries, drugs, devices and procedures that improve health throughout the world. That’s one feature of American health care we should not throw out with the bath water. In a new study for the Cato Institute, we compare the U.S. to other nations by their contributions to basic medical sciences, diagnostics, therapeutics, and business models. With the exception of business model innovation (which appears sluggish across nations), the U.S. has contributed more in these areas than any other country–and sometimes more than all other countries combined. Take basic medical sciences, meaning advances in our understanding of disease and the human body. As measured by Nobel Prizes in medicine and physiology, the U.S. leads the world: 57 U.S.-based prize winners in the last four decades, compared with just 40 from other nations. How about diagnostics and therapeutics, which help doctors identify and treat disease? Of the top 27 diagnostic and therapeutic innovations over the past four decades, work in the U.S. contributed significantly to 20, including nine of the top 10. By contrast, all European Union countries together with Switzerland had a hand in 14 of those advances, and just five of the top 10. Important innovations developed solely in the U.S. include drugs like ACE inhibitors for heart failure and high blood pressure, selective serotonin reuptake inhibitors for depression, and treatments for cataracts. Why does America outpace the rest of the world in medical innovation? It’s not our large population. The combined population of the E.U. and Switzerland exceeds the U.S. population by more than 50%. Many characteristics of a country can affect innovation, including the patent system, tax code, medical culture, general business climate and quality of universities. But health care policy surely plays a major role. It seems likely that American medical innovation is driven largely by something often regarded as a defect: the fact that we spend so much money. The NIH spends more than $30 billion annually on research in basic medical sciences, while its counterparts in Europe spend $3 billion to $4 billion annually. Additionally, centrally organized health care systems, like those in much of Europe, are characterized by strong buyer power that pushes down compensation. As a result, they pay 35% to 55% less for prescription drugs. Centralized systems also place limits on the use of new drugs, technologies and procedures. As a result, they tend to adopt new technologies later and use them less extensively. Lower spending might seem like a good thing, until you consider the poor incentive it creates for innovation. Other things equal, people and firms tend to invest more in medical innovation when they expect a higher return, when the returns last longer and when the returns arrive sooner. As Sidney Taurel, former CEO of the pharmaceutical giant Eli Lilly , once put it: America, “though hardly ‘free’ of government intervention … is the one market where global innovators find the incentive they need to keep pushing the boundaries.” Critics often describe America’s high level of per-capita medical spending as a problem–but when encouraging innovation, it’s a feature.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---US Key

US is key---innovation profits fund research abroad

Tomas J. Philipson 10, Ph.D., is the Daniel Levin Professor of Public Policy at The University of Chicago and The Chairman of Project FDA of The Manhattan Institute. 4/23/10, “We Can't Lose Our Global Leadership In Medical Innovation” http://www.foxnews.com/opinion/2010/04/23/tomas-philipson-obamacare-health-care-europe-medical-innovation.html

Has Europe found some new way to have their cake and eat it too – enjoying both lower costs and high levels of innovation?

In a word, no. Solidarity is cheap in Europe, but only because it is expensive in the U.S. The United States generates the lion’s share of global profits for medical innovators, because so far U.S. policymakers have rejected explicit price controls on private markets. For example, more than half the world’s sales of drugs occur in the U.S., even though the U.S. represents only about one-fifth of the world economy. Profits generated in the United States allow innovators across the world to fund the expensive R&D efforts that are critical for bringing innovative new medicines to market.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---IL---Bioterror

Innovation is targeted to stop bioterror now

Genia Long 13, is an expert in the economics and business strategy of innovation and growth. She has assisted executives in pharmaceuticals and biotechnology related fields. Works for Analysis Group. 2013. “Innovation in the Biopharmaceutical Pipeline: A Multidimensional View” http://phrmadocs.phrma.org/sites/default/files/pdf/2013innovationinthebiopharmaceuticalpipeline-analysisgroupfinal.pdf

There are also a range of medicines in development in areas relevant to the needs of national security, the United States military, and victims of natural disasters. For example, research is under way to address various potential bioterrorism agents, which may cause death or disease in humans, animals, or plants.

While the most recently FDA-approved treatment for anthrax, a highly dangerous, potential bioterrorism

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---IL---Bioterror

Innovation is key to biodefense

Joe Lieberman 15, and Tom Ridge cochair the Blue Ribbon Study Panel on Biodefense. Lieberman (D-CT) served 24 years in the United States Senate, where he spent six years as Chairman of the Senate Committee on Homeland Security and Governmental Affairs. 10/28/15, “Opinion: Biodefense Innovation Needed” http://www.the-scientist.com/?articles.view/articleNo/44354/title/Opinion--Biodefense-Innovation-Needed/

Exposure to novel microbes is not just an extraterrestrial concern. Pathogens seriously impact human health each day. Biodefense is the field of activity in which we work to predict, prevent, and respond to major infectious disease threats, whether they come from nature, terrorists, or lab accidents. Civilian and military planners determine which biological threats are most likely, and then develop the detectors and medical countermeasures needed to thwart them. Although their specific needs are different from NASA’s, their fundamental need to identify unknown organisms quickly is the same.

While the terrestrial approach may be logical for known threats, it requires currently unsustainable resources to address thousands of individual organisms known to cause morbidity and mortality. Organism-specific detection technology and laboratory protocols will prove insufficient to meet unsuspected or bioengineered threats. Threats from emerging diseases, genetic engineering, and antimicrobial resistance require a shift in thinking to address previously unseen organisms. What if today’s civilian and military agencies employed lateral thinking to develop capacities needed to rapidly identify immunogenic components of pathogens, deliver antigen payloads into platform technologies, and quickly manufacture medical countermeasures using flexible and adaptable technologies.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › --AT University/Gov Solves---Industry Key

Univeristy and government led innovation fails---industry is key to new treatments

Thomas Stossel 17, is the Director of the Translational Medicine Division and Senior Physician in Hematology at Brigham & Women's Hospital, Harvard Medical School. 1/4/17, “Removing barriers to medical innovation” http://www.aei.org/publication/912939/

Enormous improvements in human health have taken place over the last half-century. Americans live, on average, a decade longer. The most prevalent cause of mortality in the United States — cardiovascular disease, which causes heart attacks and strokes — has decreased by over 50%. Cancer, the number-two cause, has become far more treatable, and cancer mortality rates have plummeted in recent years. A few decades ago, it was common to see individuals whom arthritis had deformed and condemned to immobility and chronic pain. Now, such victims are uncommon. Mental-hospital wards that used to house patients with intractable psychoses and depression either sit empty or have been repurposed. The outbreak of the HIV/AIDS epidemic in the 1980s elicited apocalyptic predictions that it would bankrupt the health-care system. But within two decades, many HIV-infected individuals were living normal, albeit medicated lives.

The driving force behind these remarkable improvements is unquestionably medical innovation: new technologies including medications, medical devices, and improved medical procedures. But most people are unaware of who or what deserves our gratitude for these advances.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › --AT University/Gov Solves---Industry Key

Government subsidization of medical innovation gets politicized---only market signals drive innovation in the right areas

The Economist 7---The economist is an award winning magazine. 4/16/07, “In the name of innovation” https://www.economist.com/blogs/freeexchange/2007/04/in_the_name_of_innovation

Can't the government just replace the lost spending? Then we could have all the drugs, without the nasty marketing spending! There are several potential answers to this.

The marketing spending isn't all it's cracked up to be; a huge percentage of it is free samples, which we don't want to stop.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---IL---Disease

An innovative drug pipeline is the only defense against new superbugs---novel treatments overcome ABR

Kathy Talkington 16, Pew Charitable Trust Project Director. 12/20/16, “Tracking the Pipeline of Antibiotics in Development” http://www.pewtrusts.org/en/research-and-analysis/collections/2016/12/tracking-the-pipeline-of-antibiotics-in-development

Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. A majority of doctors have encountered patients with infections that do not respond to available treatments, and when new drugs come to market bacteria can quickly develop resistance. According to a report from the Centers for Disease Control and Prevention, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and at least 23,000 die as a result. A sustained and robust pipeline of new antibacterial drugs and novel therapies is critical to ensure that new interventions keep pace with these evolving pathogens.

2023 Northwestern Affirmative
Case › Disease Advantage---Offense › 2NC---IL---Disease

Innovation into non-traditional medical products prevents pandemics from taking hold in the first instance

Carolyn Shore 17, Pew Charitable trust Anti-Biotic Resistance Project, Director, Forum on Drug Discovery, Development, and Translation - ‎The National Academies of Sciences, Engineering, and Medicine. 5/22/17, “Nontraditional Products in Development to Treat or Prevent Bacterial Infections” http://www.pewtrusts.org/en/research-and-analysis/analysis/2017/05/17/nontraditional-products-in-development-to-treat-or-prevent-bacterial-infections

While antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—remains essential to combating antibiotic resistance, “outside-the-box” approaches to preventing and treating bacterial infections are also needed. Such nontraditional approaches encompass a variety of products, including:

Well-known medical interventions, such as vaccines and immunotherapies, that have been proved effective in treating other types of disease and may also hold promise for the prevention or treatment of systemic (throughout the body) bacterial infections.